Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 11/20 | 0.46 |
| ▸ | TAB1 | Q15750 | 11/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18238751 | 1.00 | MAP3K7 (0.46) | MAP3K7TAB1TDO2NTRK1GSK3B | |
| SCHEMBL18250526 | 0.90 | TDO2 (0.40) | MAP3K7TAB1TDO2NTRK1GSK3B | |
| SCHEMBL16945189 | 0.87 | MAP3K7 (0.46) | MAP3K7TAB1TDO2NTRK1GSK3B | |
| SCHEMBL18238269 | 0.87 | MAP3K7 (0.46) | MAP3K7TAB1TDO2NTRK1GSK3B | |
| SCHEMBL16932992 | 0.81 | AXL (0.44) | MAP3K7TAB1TDO2NTRK1GSK3B | |
| SCHEMBL16932991 | 0.81 | AXL (0.44) | MAP3K7TAB1TDO2NTRK1GSK3B | |
| SCHEMBL16945143 | 0.81 | MAP3K7 (0.53) | MAP3K7TAB1NTRK1GSK3B | |
| SCHEMBL18238627 | 0.81 | MAP3K7 (0.53) | MAP3K7TAB1NTRK1GSK3B | |
| SCHEMBL24197757 | 0.79 | MAP3K7 (0.46) | MAP3K7TAB1TDO2GSK3BCLK1 | |
| SCHEMBL18250523 | 0.77 | GSK3B (0.41) | MAP3K7TAB1TDO2NTRK1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499551-B2 | Substituted pyrrolo[2,3-b]pyridines for treating cancer or inflammatory diseases | CONFLUENCE LIFE SCIENCES, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499551-B2 | Substituted pyrrolo[2,3-b]pyridines for treating cancer or inflammatory diseases | CONFLUENCE LIFE SCIENCES, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499551-B2 | Substituted pyrrolo[2,3-b]pyridines for treating cancer or inflammatory diseases | CONFLUENCE LIFE SCIENCES, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150210705-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES | ACLARIS THERAPEUTICS, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150210705-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES | ACLARIS THERAPEUTICS, INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2015112854-A1 | SUBSTITUTED PYROOLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES | CONFLUENCE LIFE SCIENCES, INC. (US) | 2015-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210705-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES | TPMT, MALT1, IRAK4 | MAP3K7 152/4885TAB1 861/4885TDO2 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.